SCR
Simcere Pharmaceutical GroupNYSE
SCR is defunct.
  • Aug. 28, 2013, 7:20 AM
    • China's Simcere Pharmaceutical (SCR) has agreed to be taken private by a consortium that includes founder and Chairman Jinsheng Ren in a deal worth $495.4M.
    • The buyout group, which already owns 78% of the company, is offering $9.66 per ADS, or a premium of 3% to the company's close of $9.36 yesterday. The price is also above a previous offer of $9.56. (PR)
    | Aug. 28, 2013, 7:20 AM
  • Aug. 13, 2013, 1:33 PM
    • Simcere Pharmaceutical (SCR -0.7%) slips after its Q2 earnings miss on both EPS and revenue estimates.
    • Total revenue slid 3% Y/Y, negatively impacted by the government's pricing policy, government restrictions on the use of antibiotics and market competition.
    • Gross margin from continuing operations decreased to 83.1%, compared to 84.5% for the same period in 2012.
    | Aug. 13, 2013, 1:33 PM
  • Aug. 13, 2013, 7:36 AM
    • Simcere Pharmaceutical (SCR): Q2 EPS of $0.03 misses by $0.09.
    • Revenue of $78.7M misses by $12.88M. (PR)
    | Aug. 13, 2013, 7:36 AM
  • Jun. 24, 2013, 7:49 AM

    China-focused Simcere Pharmaceuticals (SCR) divests its stake in Jilin Boda Pharmaceuticals for ~$65.1M. (PR)

    | Jun. 24, 2013, 7:49 AM
  • May 9, 2013, 6:42 AM
    Simcere Pharmaceuticals (SCR): Q1 EPS of $0.09 beats by $0.01. Revenue of $85.1M. (PR)
    | May 9, 2013, 6:42 AM
  • Mar. 11, 2013, 12:56 PM
    Midday top 10 gainers: CALI +52%. BOSC +45%. ESYS +30%. CBMX +25%. LAS +25%. PAMT +15%. FONR +15%. SCR +15%. SGOC +15%. RWC +14%.
    Midday top 10 losers: AEZS -21%. NSU -11%. CSIQ -11%. SPEX -11%. FREE -10%. DKS -10%. CERE -10%. CNIT -9%. ONP -9%. RDCM -8%.
    | Mar. 11, 2013, 12:56 PM
  • Mar. 11, 2013, 8:29 AM

    Simcere Pharmaceutical (SCR) jumps 16.2% to $9.25 after the Chinese company receives a buyout offer of $9.56/ADS from a consortium led by its chairman, Jinsheng Ren. The bid represents a premium of 19% on Simcere's Friday close of $7.96 and values the firm at $500M. The firm has appointed a committee of independent directors to analyze the offer. (PR)

    | Mar. 11, 2013, 8:29 AM
  • Mar. 7, 2013, 2:37 PM

    Simcere Pharmaceutical (SCR -0.3%) slips after reporting a Q4 loss of $0.06 per ADS, versus flat consensus estimates, primarily due to a non-cash impairment charge of as the result of a write-down of intangible assets, goodwill, and assets held for sale associated with the acquisition of Jiangsu Quanyi Biological Technology. Gross margin also fell to 81.1%, compared to 82.3%. Read more on earnings here: Earnings Call Transcript.

    | Mar. 7, 2013, 2:37 PM
  • Mar. 7, 2013, 5:29 AM
    Simcere Pharmaceutical (SCR): Q4 Preliminary EPS of -$0.06. Preliminary Revenue of $86.7M (+5.7% Y/Y). (PR)
    | Mar. 7, 2013, 5:29 AM
  • Nov. 15, 2012, 6:52 AM
    Simcere Pharmaceutical (SCR): Q3 EPS of $0.07. Revenue of $83.8M (+5.1% Y/Y). (PR)
    | Nov. 15, 2012, 6:52 AM
  • Aug. 10, 2012, 5:52 AM
    Simcere Pharmaceutical (SCR): Q2 EPS of $0.04 misses by $0.06. Revenue of $83.2M (-1.4% Y/Y) misses by $3M. (PR)
    | Aug. 10, 2012, 5:52 AM
  • May 9, 2012, 6:03 AM
    Simcere Pharmaceutical (SCR): Q1 EPS of $0.08 in-line. Revenue of $77.4M (+5.2% Y/Y) misses by $7M. (PR)
    | May 9, 2012, 6:03 AM
  • Mar. 7, 2012, 7:43 AM
    Simcere Pharmaceutical (SCR): Q4 EPS of $0.12 beats by $0.07. Revenue of $81.2M (-9.2% Y/Y) misses by $6M. (PR)
    | Mar. 7, 2012, 7:43 AM
  • Nov. 16, 2009, 12:05 AM

    Notable premarket earnings: LOW, PWRD, SOL, SCR

    | Nov. 16, 2009, 12:05 AM